Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
about
ABL tyrosine kinases: evolution of function, regulation, and specificityNilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemiaAntitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 studyAP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceNew Developments in Chronic Myeloid Leukemia: Implications for TherapyCancer Stem Cell Hierarchy in Glioblastoma MultiformeMorphogenetic fields in embryogenesis, regeneration, and cancer: non-local control of complex patterningResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsConformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase DomainCharacteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.Resistant mutations in CML and Ph(+)ALL - role of ponatinib.Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.Overcoming mutation-based resistance to antiandrogens with rational drug designCurrent developments in molecular monitoring in chronic myeloid leukemiaModeling of Chronic Myeloid Leukemia: An Overview of In Vivo Murine and Human Xenograft ModelsSecondary mutations as mediators of resistance to targeted therapy in leukemiaStochastic Tunneling of Two Mutations in a Population of Cancer CellsNMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors.ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1.Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasThe role of genetic diversity in cancer.Aurora kinase inhibitors--rising stars in cancer therapeutics?Toward the design of mutation-resistant enzyme inhibitors: further evaluation of the substrate envelope hypothesis.The mutator phenotype in cancer: molecular mechanisms and targeting strategiesTargeting the cancer kinome through polypharmacology.Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cellsMechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance.Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research.Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.Cancer stem cell plasticity and tumor hierarchy.Progress in understanding melanoma propagation.Targeted inhibition of kinases in cancer therapyEndogenous Voltage Potentials and the Microenvironment: Bioelectric Signals that Reveal, Induce and Normalize Cancer.Monitoring response and resistance to treatment in chronic myeloid leukemia.Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapyThe novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
P2860
Q24299738-DF9F048C-BB4C-414A-B1A8-CFE3EF14BDE0Q24299821-5B9F75C7-41D4-48EC-AD1D-2B15AB59FD88Q24596926-87D3E682-E8EF-4932-9E3B-D97B0B59ADF3Q24648017-170D1FAE-DB33-4984-8397-5CB8A7B51D88Q26745669-E8354951-113B-4FF2-8E46-053154BF843FQ26752312-B0F771B4-5C1C-439D-9BF5-9EBB73A22118Q27023511-3CD7CA5D-500E-496E-93F5-F2122939D945Q27028181-CC7FC165-F869-448F-9BA6-46A606C167F8Q27667482-1E5F1593-562D-43F4-840B-C8EA04E293B1Q27678454-667630CE-8ED6-4A54-973E-27405253947AQ27851450-C5B9E3B0-6DA9-4AE2-B602-CAF20F65AE61Q27853085-D58F761C-AF68-44A6-AD78-F7203C20939AQ27853214-8A559DA9-6F7E-4FF2-8535-C228CB0980B3Q28044590-88A4C0AB-79C9-4A76-BFF6-72C671D856A0Q28066148-DA84FBF7-A910-4A45-A290-1F0CE2A24B33Q28076328-20A7E5B2-C5D9-4A7C-B15A-5BFA259EB156Q28087213-5F7054DC-2086-471B-A0AF-4CCAA4E90D5EQ28534328-ADB6EEA0-9BA7-4612-804D-5A51702C88F9Q30009530-30AD5A1B-F51F-4F5D-BBF5-9E9B1DB4575FQ30155948-29EB1E81-D526-4453-A833-6957DA9CD198Q33398716-F44E3D9E-E1AE-4DB6-9AD5-DFF320F9E719Q33411250-3DDFB9D5-74A3-4C00-8DCF-B680E78C4C02Q33604953-37278766-B2CF-4CE6-B0F5-F492DE59311BQ33647643-C9C8FB90-7C53-412B-9D40-F1EDE802D0A8Q33815097-04766654-F480-4E4F-952D-C43A7D37BABEQ33815796-AE24406A-96EB-4DED-B5A1-8AAE7B65DC6FQ33893019-A46B9EFE-FFF3-4B16-8BF3-8A306427A0E6Q33907178-852F75F3-3C0D-4A89-B327-6DA0510132D2Q34016866-A27B55E7-4797-4C4C-A4DA-08795E672802Q34060618-63A0B511-222C-4803-B410-93ECAA03FBC9Q34085685-6D42ED76-F876-479E-A686-A0757E6B0690Q34293414-F35D8717-5E6D-470F-9A0C-03553C1DC068Q34417824-ACE51135-8D06-40F5-BFDC-316ACF3B67AAQ34459650-FEA3ED17-1B7E-405D-AD6F-7E68B16BE397Q34552547-D4B064A0-B943-4144-90C9-F920B0D7BA97Q34683348-E34670B4-ED4D-4A4A-815A-5CBBB9B731D6Q34710990-AD159436-3AEF-4A9A-AFF7-4D51E2AF0639Q34761663-4D754DC7-E3BE-476F-B631-AEB6E20FB555Q35018557-3B5D04DA-0774-4F8A-A20B-7E49EA2BF9ABQ35377275-6658E01F-EC01-4D04-AB8C-4DF475E388B4
P2860
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Sequential ABL kinase inhibito ...... with altered oncogenic potency
@ast
Sequential ABL kinase inhibito ...... with altered oncogenic potency
@en
Sequential ABL kinase inhibito ...... with altered oncogenic potency
@nl
type
label
Sequential ABL kinase inhibito ...... with altered oncogenic potency
@ast
Sequential ABL kinase inhibito ...... with altered oncogenic potency
@en
Sequential ABL kinase inhibito ...... with altered oncogenic potency
@nl
prefLabel
Sequential ABL kinase inhibito ...... with altered oncogenic potency
@ast
Sequential ABL kinase inhibito ...... with altered oncogenic potency
@en
Sequential ABL kinase inhibito ...... with altered oncogenic potency
@nl
P2093
P2860
P3181
P356
P1476
Sequential ABL kinase inhibito ...... with altered oncogenic potency
@en
P2093
Brian J Skaggs
Charles L Sawyers
John M Nicoll
Neil P Shah
Ronald L Paquette
Susan Branford
Timothy P Hughes
P2860
P304
P3181
P356
10.1172/JCI30890
P407
P577
2007-09-01T00:00:00Z